FELIPE DE ARRIBA DE LA FUENTE

Guerrero C, Puig N, Cedena MT, Calasanz MJ, Gutierrez NC, Fernandez M, Oriol A, Rios-Tamayo R, Hernandez Garcia MT, Martinez-Martinez R, Bargay J, de Arriba F, Palomera L, Gonzalez-Rodriguez AP, Gonzalez Perez MS, Orfao A, Mateos MV, Martinez-Lopez J, Rosinol L, Blade J, Lahuerta JJ, San-Miguel J, Paiva B. Predictors of unsustained measurable residual disease negativity in transplant-eligible multiple myeloma patients. Blood. 2023 Dec 4:blood.2023022083. doi: 10.1182/blood.2023022083. Online ahead of print. PubMed PMID: 38048552.

AÑO: 2023; IF: 20.3

38048552

Tamariz-Amador LE, Rodriguez-Otero P, Jimenez-Ubieto A, Rosinol L, Oriol A, Rios R, Sureda A, Blanchard MJ, Hernandez MT, Cabanas Perianes V, Jarque I, Bargay J, Gironella M, De Arriba F, Palomera L, Gonzalez-Montes Y, Marti JM, Krsnik I, Arguinano JM, Gonzalez ME, Casado LF, Gonzalez-Rodriguez AP, Lopez-Anglada L, Puig N, Cedena MT, Paiva B, Mateos MV, San-Miguel J, Lahuerta JJ, Blade J, Troconiz IF. Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2022 Sep;22(9):e844-e852. doi: 10.1016/j.clml.2022.04.024. Epub 2022 May 5. PubMed PMID: 35688793.

AÑO: 2022; IF: 2.7

35688793

Termini R, Zihala D, Terpos E, Perez-Montana A, Jelinek T, Raab M, Weinhold N, Mai EK, Grab AL, Corre J, Vergez F, Sacco A, Chiarini M, Giustini V, Tucci A, Rodriguez S, Moreno C, Perez C, Maia C, Martin-Sanchez E, Guerrero C, Botta C, Garces JJ, Lopez A, Tamariz-Amador LE, Prosper F, Bargay J, Cabezudo ME, Ocio EM, Hajek R, Martinez-Lopez J, Solano F, Iglesias R, Paiva A, Geraldes C, Vitoria H, Gomez C, De Arriba F, Ludwig H, Garcia-Guinon A, Casanova M, Alegre A, Cabanas V, Sirvent M, Oriol A, de la Rubia J, Hernandez-Rivas JA, Palomera L, Sarasa M, Rios P, Puig N, Mateos MV, Flores-Montero J, Orfao A, Goldschmidt H, Avet-Loiseau H, Roccaro AM, San-Miguel JF, Paiva B; PETHEMA/GEM and iMMunocell Cooperative Groups. Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma. Clin Cancer Res. 2022 Nov 1;28(21):4771-4781. doi: 10.1158/1078-0432.CCR-22-1594. PubMed PMID: 36074126.

AÑO: 2022; IF: 11.5

36074126

Mateos MV, Hernandez MT, Salvador C, Rubia J, de Arriba F, Lopez-Corral L, Rosinol L, Paiva B, Palomera L, Bargay J, Oriol A, Prosper F, Lopez J, Arguinano JM, Blade J, Lahuerta JJ, San-Miguel J. Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study. Eur J Cancer. 2022 Oct;174:243-250. doi: 10.1016/j.ejca.2022.07.030. Epub 2022 Sep 5. PubMed PMID: 36067617.

AÑO: 2022; IF: 8.4

36067617

Guerrero C, Puig N, Cedena MT, Goicoechea I, Perez C, Garces JJ, Botta C, Calasanz MJ, Gutierrez NC, Martin-Ramos ML, Oriol A, Rios R, Hernandez MT, Martinez-Martinez R, Bargay J, de Arriba F, Palomera L, Gonzalez-Rodriguez AP, Mosquera-Orgueira A, Gonzalez-Perez MS, Martinez-Lopez J, Lahuerta JJ, Rosinol L, Blade J, Mateos MV, San-Miguel JF, Paiva B. A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma. Clin Cancer Res. 2022 Jun 13;28(12):2598-2609. doi: 10.1158/1078-0432.CCR-21-3430. PubMed PMID: 35063966.

AÑO: 2022; IF: 11.5

35063966